Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The findings are published in the July 20 online issue of Nature.
UC San Diego researchers led by Jeff Hasty, a professor of bioengineering and biology, engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The team then transferred the bacterial therapy to their MIT collaborators for testing in an animal model of colorectal metastasis. The design of the therapy represents a culmination of four previous Nature papers from the UC San Diego group that describe the systematic development of engineered genetic clocks and synchronization. Over the years, the researchers have employed a broad approach that spans the scales of synthetic biology,
The new study offers a therapeutic approach that minimizes damage to surrounding cells.
“In synthetic biology, one goal of therapeutics is to target disease sites and minimize damage,” said UC San Diego bioengineering and biology professor Jeff Hasty. He wondered if a genetic “kill” circuit could be engineered to control a population of bacteria in vivo, thus minimizing their growth. “We also wanted to deliver a significant therapeutic payload to the disease site.”
In order to achieve this, he and his team synchronized the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumor environment. The use of bacteria to deliver cancer drugs in vivo is enticing because conventional chemotherapy doesn’t always reach the inner regions of a tumor, but bacteria can colonize there. Importantly, the researchers observed that the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumor size.
“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a professor at MIT who is known as a founder of the field of synthetic biology. “Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronizing cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”
Limiting the bacterial population
In order to observe the bacterial population dynamics, the researchers designed custom microfluidic devices for careful testing before investigations in animal disease models. Consistent with the engineering design, they observed cycling of the bacterial population that successfully limits overall growth while simultaneously enabling production and release of encoded cargo. When the bacteria were equipped with a gene that drives production of a therapeutic, the synchronized lysis of the bacterial colony was shown to kill human cancer cells. It is the first engineered gene circuit in synthetic biology to achieve these objectives.
The Latest on: Synthetic biology
via Google News
The Latest on: Synthetic biology
- IISER Pune team wins gold at iGEM 2020 synthetic biology competitionon November 26, 2020 at 10:52 pm
A team of 14 students from Indian Institutes of Science Education and Research (IISER) Pune who competed at the 2020 international Genetically E.
- TAU Students Nab Gold Medal At Synthetic Biology World Championshipon November 26, 2020 at 4:17 am
The TAU team ranked higher overall than teams from some of the world's top universities including MIT and Harvard.
- Augmentation: Top things to know before investing in Synthetic Biology Marketon November 25, 2020 at 12:42 am
Research Dive –:The global synthetic biology market is estimated to surpass $30,479.5 million by 2027, exhibiting a CAGR of 23.9% from 2020 to 2027.The report aims to offer a clear picture of the ...
- TAU students win gold medal at iGEM – the World Championship in Synthetic Biologyon November 24, 2020 at 4:00 pm
The technology developed by the TAU team, based on tools from various disciplines, comprises software for designing genetically stable DNA sequences, alongside novel techniques for measuring genome ...
- As a Wiser World Looks to Make a Strong Sustainable Recovery From COVID-19, Synthetic Biology to Receive New Opportunities for Growthon November 24, 2020 at 8:32 am
Stock quotes by finanzen.net New York, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Synthetic Biology Industry" - With humans continuing their ...
- IISER Pune team wins gold at the iGEM 2020 synthetic biology competitionon November 23, 2020 at 8:01 am
A team of 14 students from Indian Institute of Science Education and Research (IISER) Pune who competed at the 2020 international Genetically En.
- Li Ka Shing's bet on the future is synthetic biology, with Horizons' investments in faux meat, plant milk and molecular whiskeyon November 22, 2020 at 6:20 pm
Impossible Foods’ vice-president Nick Halla had the tables turned on him in early 2014 during a pitch of his three-year-old start-up to one of the world’s most powerful venture capital ...
- Army’s ‘Team Ignite’ Focusing on AI, Synthetic Biologyon November 20, 2020 at 10:12 am
Discussions in previous workshops have ranged from synthetic biology and quantum sciences to alternative sources of power and energy, he noted. To help prepare the military to combat adversaries, Team ...
- Teach Me in 10 – Why Synthetic Biology Will Eat Your Fields With Dr Jake Wintermuteon November 18, 2020 at 4:00 pm
In this installment of Teach Me in 10, Dr Wintermute provides a Synthetic Biology 101, teaching you everything that you need to know about this interesting area of science, in less than 10 minutes.
- Synthetic Biology Market Players to Project Agriculture Application as a Viable Investment Portfolio Through 2025on November 17, 2020 at 10:16 pm
Global Market Insights, Inc :With the focus on technologies for building and designing biological organisms soaring, stakeholders have upped their investments in synthetic biology industry. Synthetic ...
via Bing News